6,963 publications from this institution
We have investigated the effect of IL-1 β on histamine H1-receptor (H1R)-mediated inositol phosphate (IP) accumulation in human airway smooth muscle cells (HASMC) and on histamine-induced contraction of human bronchial rings. Stimulation of HASMC for 24 h with IL-1 β resulted in significant loss of histamine-induced IP formation, which was associated with a reduction of histamine- induced contraction of IL-1 β -treated human bronchial rings. An inhibitor of NF- κ B activation, pyrrolidine dithiocarbamate, and a p38 MAPK inhibitor, blocked the IL-1 β -induced H1R desensitization, whereas anisomycin, an SAPK/JNK and p38 MAPK activator, mimicked the effect of IL-1 β . IL-1 β has been demonstrated to induce cox-2 expression and PGE2 synthesis. In our study, indomethacin a cox antagonist, completely inhibited the effect of IL-1 β on H1R, whereas exogenously added PGE2 was able to desensitize H1R. Furthermore, H-89, a selective PKA inhibitor, antagonized the effect of IL-1 β . Here, we have demonstrated that IL-1 β desensitizes H1R, which involves the activation of p38 MAPK and NF- κ B, leading to the expression of cox-2 and the synthesis of PGE2. PGE2 increases intracellular cAMP resulting in PKA activation, which phosphorylates and functionally uncouples H1R. Our results suggest that IL-1 β protects airway smooth muscle against histamine-induced contractile responses and that bronchial hyperreactivity to histamine is not associated with proinflammatory cytokine-induced enhancement in H1R signaling.
The inability to optimise stent expansion fully whilst simultaneously preventing distal embolisation during ST-elevation myocardial infarction (STEMI) remains a clinical conundrum. We aimed to describe a newly devised angiographic strategy of "forward" and "back" aspiration that leads to more complete thrombus removal and prevention of distal embolisation, to allow high-pressure post-dilatation of the implanted stent to be performed.Forward aspiration was conducted with a conventional aspiration thrombectomy catheter, with bail-out aspiration thrombectomy for angiographically persistent thrombus utilising the larger bore 6 Fr (0.056") guide catheter extension system (GuideLiner; Vascular Solutions, Inc., Minneapolis, MN, USA). Back aspiration was undertaken with a deeply intubated GuideLiner or guide catheter with a vacuum induced within, extending to the inflated angioplasty balloon, to allow for proximal embolic protection during balloon deflation during all stages of the PCI procedure, including high-pressure post-dilatation of the stent to the visually estimated reference vessel diameter (RVD). Over a six-month period 30 consecutive cases were undertaken during working hours. Bail-out GuideLiner-assisted aspiration thrombectomy was performed in 9/30 cases because of inadequate thrombus removal with a conventional aspiration thrombectomy catheter. Back aspiration was performed in all cases. In 27/30 cases high-pressure post-dilatation of the stent was performed. The mean maximum post-dilatation balloon size and mean proximal reference vessel diameter did not significantly differ (3.60±0.41 mm vs. 3.65±0.45 mm, p=0.68). In all cases, implantation +/- post-dilatation of the stent to the visually estimated RVD was achievable without any deterioration in TIMI blood flow or myocardial blush grade.The strategy of forward and back aspiration to facilitate stent implantation and high-pressure post-dilatation during STEMI appears to be safe and effective. Randomised controlled trials are required to confirm the safety and efficacy of this newly devised angiographic strategy.
A new nickel-free austenitic stainless steel EN 1.4678 (Forta H500) with excellent corrosion resistance and significant strain hardening has been recently developed, but its elevated temperature behaviour has yet to be investigated. This paper reports an experimental study into the material properties of EN 1.4678 stainless steel at elevated temperatures. 22 coupons were extracted from 6 mm EN 1.4678 stainless steel plates and tested to failure at temperatures up to 1000°C. Elevated temperature reduction factors for the key material properties were derived and compared to corresponding factors for stainless steel specified in existing standards. The average experimentally derived reduction factors and the Ramberg-Osgood material model for stainless steel were applied in the FE modelling of hybrid carbon steel-stainless steel end-plate connections in fire, with a view to exploiting the excellent elevated temperature behaviour of stainless steel to improve the response of connections in steel framed structures in fire.
Objectives This paper reports the 3-year clinical outcomes of the XIENCE V (Abbott Vascular, Santa Clara, California) everolimus-eluting stent (EES) compared with the TAXUS (Boston Scientific, Natick, Massachusetts) paclitaxel-eluting stent (PES) in the randomized SPIRIT II (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions) study. Background The Xience V EES is a new-generation drug-eluting stent (DES) that might offer advantages over the first-generation DES in terms of improved clinical outcomes and a better safety profile. Methods The SPIRIT II trial was a multicenter, prospective, randomized, single-blind, clinical trial, randomizing 300 patients with de novo coronary artery lesions in a ratio of 3:1 to either EES or PES. The primary end point was in-stent late loss at 180 days. Results At 3-year clinical follow-up cardiac death was numerically lower with EES than PES (0.5% vs. 4.3%, p = 0.056). The observed rate of myocardial infarction was 3.6% for EES and 7.2% for PES (p = 0.31). The rate of ischemia-driven target lesion revascularization was 4.6% and 10.1% for EES and PES, respectively (p = 0.14). Overall, there was a trend for lower major adverse cardiovascular events in the EES group compared with PES (7.2% vs. 15.9%, p = 0.053). The rate of stent thrombosis was low and comparable in both groups (EES 1.0% vs. PES 2.9%). Conclusions The present study reports the favorable 3-year clinical outcomes of the EES, which are consistent with the results from other studies of the EES with shorter follow-up.
No abstract is provided for this article.
Conference Abstract| January 01 1985 The Effect of Vasoactive Intestinal Peptide on Human Airway Smooth Muscle in-vitro J.B. Palmer; J.B. Palmer 1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 OHS Search for other works by this author on: This Site PubMed Google Scholar F.M. Cuss; F.M. Cuss 1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 OHS Search for other works by this author on: This Site PubMed Google Scholar P.J. Barnes P.J. Barnes 1Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 OHS Search for other works by this author on: This Site PubMed Google Scholar Clin Sci (Lond) (1985) 68 (s11): 58P. https://doi.org/10.1042/cs068058Pa Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Twitter LinkedIn Cite Icon Cite Get Permissions Citation J.B. Palmer, F.M. Cuss, P.J. Barnes; The Effect of Vasoactive Intestinal Peptide on Human Airway Smooth Muscle in-vitro. Clin Sci (Lond) 1 January 1985; 68 (s11): 58P. doi: https://doi.org/10.1042/cs068058Pa Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Science Search Advanced Search This content is only available as a PDF. © 1985 The Biochemical Society and the Medical Research Society1985 Article PDF first page preview Close Modal You do not currently have access to this content.